Welcome to Crene Biotechnology!
Login| 中文| English

+86-576-88205808

Cart(0)
HOME
ABOUT CRENE
PRODUCTS
NEW&EVENTS
CUSTOM SYNTHESIS
ORDER INFORMATION
CONTACT US
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product :

VcMMAE mc-vc-PAB-MMAE

VcMMAE mc-vc-PAB-MMAE 646502-53-6
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name：VcMMAE mc-vc-PAB-MMAE Purity：99% min
CAS NO：646502-53-6 Solubility：DMSO : ≥ 54 mg/mL (41.01 mM)
Molecular Formula：C68H106N11O15 Package：Package according to customer requirements
Molecular Weight：1317.63 Storage：Store at -20℃
Quality control
Remarks
VcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
References

[1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.

[2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link：
Home| About Crene| Products| New&Events| Custom Synthesis| Order Information| Contact US

Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China